Innovent Biologics, Inc. is a China-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of biologic medicines. Founded in 2011 and headquartered in Suzhou, Jiangsu, Innovent develops monoclonal antibodies and other modalities for oncology, autoimmune, metabolic, and ophthalmic diseases. The company is listed on the Hong Kong Stock Exchange (HKEX: 1801).
Innovent operates integrated R&D and GMP manufacturing facilities for large-molecule therapeutics and advances a pipeline that includes monoclonal and bispecific antibodies, antibody–drug conjugates, and other next-generation biologics. Its commercial portfolio in China includes the PD‑1 inhibitor sintilimab (Tyvyt), co-developed with Eli Lilly, and other approved biologics. Innovent also collaborates with domestic and multinational partners to expand development and access to its therapies.